Legislators Seek US FDA Input On Teva Proposed Opioid Settlement

Reps. McKinley and Kaptur ask commissioner Hahn about potential for shortages if Teva’s proposal to provide free opioid addiction treatment goes into effect. States are pushing for more money and stricter injunctive terms in settlement talks with manufacturers and distributers.

Jerusalem , Israel April 5 , 2019 . View of the Teva pharmaceutical industries headquarters in Jerusalem
Members of Congress want FDA to weigh in on Teva's opioiod settlement proposal • Source: Shutterstock

Teva Pharmaceutical Industries Ltd.’s proposal to resolve US opioid litigation with free opioid addiction treatment is facing opposition from a new front as members of Congress express concern that the plan could disrupt drug supply from other manufacturers. And in an unusual move, they are attempting to get the US Food and Drug Administration to weigh in on the plan.

Reps. David McKinley, R-WV, and Marcy Kaptur, D-Ohio, sent a 17 August letter to FDA commissioner Stephen Hahn nearly...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet